Molecular analysis of myeloid cancers, such as acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), is rapidly shifting from single-site methods such as FISH and qPCR to highly-multiplexed next-generation sequencing (NGS) assays. Hence, there is an increasing demand for highly multiplexed, patient-like NGS reference materials covering a broad range of clinically relevant variants in order to ensure that new and existing myeloid assays are robust, accurate, and consistent. SeraCare has developed the industry's first comprehensive set of myeloid cancer reference materials in response to this critical market need.
Single sample with 9 clinically-relevant RNA fusions (save $1000s in running costs)
Expert-designed to ensure coverage across important prognostic markers (such as BCR-ABL)
Built with innovative technology to produce patient-like sample characteristics and NGS assay performance
Mutation targets precisely quantitated with digital PCR
Single well-characterized GM24385 cell line as background wild-type material
Manufactured in GMP-compliant and ISO 13485-certified facilities